These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 8359571)
1. Somatostatin analogue therapy in functioning neuroendocrine gut tumors. Debas HT; Gittes G Digestion; 1993; 54 Suppl 1():68-71. PubMed ID: 8359571 [TBL] [Abstract][Full Text] [Related]
2. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors. Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934 [TBL] [Abstract][Full Text] [Related]
3. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues. Arnold R; Frank M; Kajdan U Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532 [TBL] [Abstract][Full Text] [Related]
4. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Pokuri VK; Fong MK; Iyer R Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514 [TBL] [Abstract][Full Text] [Related]
5. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Gorden P; Comi RJ; Maton PN; Go VL Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688 [TBL] [Abstract][Full Text] [Related]
6. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. Wynick D; Bloom SR J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213 [TBL] [Abstract][Full Text] [Related]
7. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide]. Arnold R; Neuhaus C; Trautmann ME Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235 [No Abstract] [Full Text] [Related]
8. [Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)]. Stöckmann F; Creutzfeldt W Z Gastroenterol; 1988 Oct; 26(10):665-75. PubMed ID: 2849248 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors. Oberg K Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573 [TBL] [Abstract][Full Text] [Related]
14. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors. Trautmann ME; Neuhaus C; Lenze H; Benning R; Benning M; Dennler HJ; Bruns C; Joseph K; Arnold R Horm Metab Res Suppl; 1993; 27():24-7. PubMed ID: 8392487 [No Abstract] [Full Text] [Related]
15. The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors. Maton PN Gastroenterol Clin North Am; 1989 Dec; 18(4):897-922. PubMed ID: 2559036 [TBL] [Abstract][Full Text] [Related]